id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-024233-hrzpxdh0	nan	In This Issue/Research Watch/News in Brief	2020-04-24		.txt	text/plain	3258	166	49	Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC Optimal treatment duration of immune checkpoint inhibitors (ICI) in non-small-cell lung cancer (NSCLC) is not well established. Hellman and colleagues evaluated blood samples using Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) of 31 advanced NSCLC patients with baseline detectable ctDNA and experiencing long-term benefit to PD-(L)1 blockade (defined as progression-free survival-PFS 12 months) in surveillance. Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer The phase III KEYNOTE 010 trial demonstrated survival improvement with pembrolizumab as compared with docetaxel in previously treated PD-L1 positive (cut-off 1%) advanced non-small-cell lung cancer (NSCLC) patients. Following this decision, brigatinib is now indicated as monotherapy for the treatment of adult patients with Anaplastic Lymphoma Kinase (ALK) positive advanced non-small-cell lung cancer previously not treated with ALK inhibitors.	./cache/cord-024233-hrzpxdh0.txt	./txt/cord-024233-hrzpxdh0.txt